Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 13, 2005. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
There are no material changes to financial performance reported. The filing details an increase in Ordinary Share ADR holdings by specific individuals following the re-investment of dividends paid on October 6, 2005. The transaction price was $51.51 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification regarding insider share transactions.
Key Facts for Investor Verification
- Transaction Type: Increase in ADR holdings via dividend re-investment.
- Transaction Price: $51.51 per ADR.
- Dividend Date: October 6, 2005.
- Participants: Dr. W. Calhoun, Dr. J.P. Garnier, Mr. D. Phelan, Dr. D. Stout, and Mr. J. Ziegler.
- Regulatory Basis: Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).